Name: TScan Therapeutics, Inc. (TCRX) Financial Statements
Creator: FinSpry

TScan Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

TScan Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	2.82	21.05	13.54	10.14	1.09
Cost of Revenue	0.00	2.88	59.82	44.95	20.58
Gross Profit	2.82	18.17	13.54	-34.81	-19.49
Operating Expenses
Research & Development	107.35	88.15	59.82	44.95	0.00
Selling, General & Administrative	29.56	25.49	20.35	13.83	6.74
Operating Expenses	137.64	114.51	80.17	13.83	6.74
Operating Income	-134.82	-93.46	-66.64	-48.64	-26.23
Other Income/Expense
Interest Income	12.07	8.00	1.59	0.02	0.11
Interest Expense	3.65	3.76	1.18	0.00	0.00
Other Income/Expense	7.32	0.00	0.00	0.00	0.00
Income
Income Before Tax	-127.50	-89.22	-66.22	-48.63	-26.13
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-127.50	-89.22	-66.22	-48.63	-26.13
Net Income - Continuous Operations	-127.50	-89.22	-66.22	-48.63	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-119.74	-80.10	-59.91	-45.31	-25.00
EBIT	-123.85	-85.46	-65.05	-48.64	-26.23
Depreciation & Amortization	4.11	0.86	5.14	3.33	1.23
Earnings Per Share
Basic EPS	-1.00	-1.00	-3.00	-4.00	-29.00
Diluted EPS	-1.00	-1.00	-3.00	-4.00	-29.00
Basic Shares Outstanding	111.99	65.60	24.05	11.66	0.92
Diluted Shares Outstanding	111.99	65.60	24.05	11.66	0.92